Kyverna Therapeutics (KYTX) Times Interest Earned (2023 - 2026)
Kyverna Therapeutics posted quarterly Times Interest Earned of -$62.02 for Q1 2026, up 96.73% year-on-year from -$31.53 in Q1 2025, and up 29.9% on a QoQ basis from -$88.47 in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Times Interest Earned data on file, last reported at -$62.02 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned rose 96.73% year-over-year to -$62.02; the trailing twelve-month figure through Mar 2026 stood at -$144.69 (up 88.92% YoY), and the FY2025 full-year result was -$347.29, up 65.42% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$62.02, up from -$88.47 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$62.02 in Q1 2026 and bottomed at -$5532.4 in Q3 2025.
- The 4-year median for Times Interest Earned is -$667.23 (2024), against an average of -$1256.7.
- The widest annual swing landed in 2025, when Times Interest Earned slumped 356.64%; it then jumped 96.73% in 2026.
- A 4-year view of Times Interest Earned shows it stood at -$454.83 in 2023, then tumbled by 234.2% to -$1520.0 in 2024, then surged by 94.18% to -$88.47 in 2025, then gained by 29.9% to -$62.02 in 2026.
- The last three Times Interest Earned figures came in at -$62.02 (Q1 2026), -$88.47 (Q4 2025), and -$5532.4 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | -62.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.02 |
| Dec 31, 2025 | -88.47 |
| Sep 30, 2025 | -5,532.43 |
| Jun 30, 2025 | -3,172.14 |
| Mar 31, 2025 | -1,896.32 |
| Dec 31, 2024 | -1,520.04 |
| Sep 30, 2024 | -1,211.56 |
| Jun 30, 2024 | -857.31 |
| Mar 31, 2024 | -667.23 |
| Dec 31, 2023 | -454.83 |
| Sep 30, 2023 | -325.64 |
| Jun 30, 2023 | -289.17 |
| Mar 31, 2023 | -260.11 |